Madrigal Pharmaceuticals (MDGL) Free Cash Flow Growth (3y) (2013 - 2026)
Powered by 
Analysis
Madrigal Pharmaceuticals (MDGL) Free Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn | -1.95% |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn | -20.15% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn | 21.16% |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | 45.09% |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn | 80.69% |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | -4.45% |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 8.92% |
| 10 | Madrigal Pharmaceuticals | 15.81 Bn | 14.97 Bn | - | 31.10% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 31.10% |
| Mar 31, 2026 | -26.76% |
| Dec 31, 2025 | -31.48% |
| Sep 30, 2025 | 49.43% |
| Jun 30, 2025 | 6.45% |
| Mar 31, 2025 | -21.17% |
| Dec 31, 2024 | -29.53% |
| Sep 30, 2024 | -14.11% |
| Jun 30, 2024 | -42.29% |
| Mar 31, 2024 | -50.95% |
| Dec 31, 2023 | -13.79% |
| Sep 30, 2023 | -21.23% |
| Jun 30, 2023 | -45.91% |
| Mar 31, 2023 | -39.74% |
| Dec 31, 2022 | -64.54% |
| Sep 30, 2022 | -73.47% |
| Jun 30, 2022 | -70.77% |
| Mar 31, 2022 | -97.16% |
| Dec 31, 2021 | -97.28% |
| Sep 30, 2021 | -105.55% |